Global Glutamate Antagonist Market Growth 2023-2029
Glutamate Antagonists work by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly classified into two main subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.
LPI (LP Information)' newest research report, the “Glutamate Antagonist Industry Forecast” looks at past sales and reviews total world Glutamate Antagonist sales in 2022, providing a comprehensive analysis by region and market sector of projected Glutamate Antagonist sales for 2023 through 2029. With Glutamate Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glutamate Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Glutamate Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glutamate Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glutamate Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glutamate Antagonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glutamate Antagonist.
The global Glutamate Antagonist market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glutamate Antagonist players cover Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH and Cerecor Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glutamate Antagonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Glutamate Antagonist market?
What factors are driving Glutamate Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glutamate Antagonist market opportunities vary by end market size?
How does Glutamate Antagonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Glutamate Antagonist Industry Forecast” looks at past sales and reviews total world Glutamate Antagonist sales in 2022, providing a comprehensive analysis by region and market sector of projected Glutamate Antagonist sales for 2023 through 2029. With Glutamate Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glutamate Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Glutamate Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glutamate Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glutamate Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glutamate Antagonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glutamate Antagonist.
The global Glutamate Antagonist market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glutamate Antagonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glutamate Antagonist players cover Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH and Cerecor Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glutamate Antagonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Ionic
- Non Ionic
- Hospitals
- Clinics
- Laboratory
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Artemis Neuroscience
- VistaGen Therapeutics
- Rottapharm Madaus
- Amorsa Therapeutics
- Newron Pharmaceuticals
- Purdue Biopharma
- Relmada Therapeutics
- BioCrea GmbH
- Cerecor Inc.
- NeurOp Inc.
- UCB SA
- Novartis AG
- Luc Therapeutics Inc.
- Evotec AG
What is the 10-year outlook for the global Glutamate Antagonist market?
What factors are driving Glutamate Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glutamate Antagonist market opportunities vary by end market size?
How does Glutamate Antagonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Glutamate Antagonist Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Glutamate Antagonist by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Glutamate Antagonist by Country/Region, 2018, 2022 & 2029
2.2 Glutamate Antagonist Segment by Type
2.2.1 Ionic
2.2.2 Non Ionic
2.3 Glutamate Antagonist Sales by Type
2.3.1 Global Glutamate Antagonist Sales Market Share by Type (2018-2023)
2.3.2 Global Glutamate Antagonist Revenue and Market Share by Type (2018-2023)
2.3.3 Global Glutamate Antagonist Sale Price by Type (2018-2023)
2.4 Glutamate Antagonist Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Laboratory
2.4.4 Others
2.5 Glutamate Antagonist Sales by Application
2.5.1 Global Glutamate Antagonist Sale Market Share by Application (2018-2023)
2.5.2 Global Glutamate Antagonist Revenue and Market Share by Application (2018-2023)
2.5.3 Global Glutamate Antagonist Sale Price by Application (2018-2023)
3 GLOBAL GLUTAMATE ANTAGONIST BY COMPANY
3.1 Global Glutamate Antagonist Breakdown Data by Company
3.1.1 Global Glutamate Antagonist Annual Sales by Company (2018-2023)
3.1.2 Global Glutamate Antagonist Sales Market Share by Company (2018-2023)
3.2 Global Glutamate Antagonist Annual Revenue by Company (2018-2023)
3.2.1 Global Glutamate Antagonist Revenue by Company (2018-2023)
3.2.2 Global Glutamate Antagonist Revenue Market Share by Company (2018-2023)
3.3 Global Glutamate Antagonist Sale Price by Company
3.4 Key Manufacturers Glutamate Antagonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glutamate Antagonist Product Location Distribution
3.4.2 Players Glutamate Antagonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLUTAMATE ANTAGONIST BY GEOGRAPHIC REGION
4.1 World Historic Glutamate Antagonist Market Size by Geographic Region (2018-2023)
4.1.1 Global Glutamate Antagonist Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Glutamate Antagonist Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Glutamate Antagonist Market Size by Country/Region (2018-2023)
4.2.1 Global Glutamate Antagonist Annual Sales by Country/Region (2018-2023)
4.2.2 Global Glutamate Antagonist Annual Revenue by Country/Region (2018-2023)
4.3 Americas Glutamate Antagonist Sales Growth
4.4 APAC Glutamate Antagonist Sales Growth
4.5 Europe Glutamate Antagonist Sales Growth
4.6 Middle East & Africa Glutamate Antagonist Sales Growth
5 AMERICAS
5.1 Americas Glutamate Antagonist Sales by Country
5.1.1 Americas Glutamate Antagonist Sales by Country (2018-2023)
5.1.2 Americas Glutamate Antagonist Revenue by Country (2018-2023)
5.2 Americas Glutamate Antagonist Sales by Type
5.3 Americas Glutamate Antagonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glutamate Antagonist Sales by Region
6.1.1 APAC Glutamate Antagonist Sales by Region (2018-2023)
6.1.2 APAC Glutamate Antagonist Revenue by Region (2018-2023)
6.2 APAC Glutamate Antagonist Sales by Type
6.3 APAC Glutamate Antagonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Glutamate Antagonist by Country
7.1.1 Europe Glutamate Antagonist Sales by Country (2018-2023)
7.1.2 Europe Glutamate Antagonist Revenue by Country (2018-2023)
7.2 Europe Glutamate Antagonist Sales by Type
7.3 Europe Glutamate Antagonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Glutamate Antagonist by Country
8.1.1 Middle East & Africa Glutamate Antagonist Sales by Country (2018-2023)
8.1.2 Middle East & Africa Glutamate Antagonist Revenue by Country (2018-2023)
8.2 Middle East & Africa Glutamate Antagonist Sales by Type
8.3 Middle East & Africa Glutamate Antagonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Glutamate Antagonist
10.3 Manufacturing Process Analysis of Glutamate Antagonist
10.4 Industry Chain Structure of Glutamate Antagonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Glutamate Antagonist Distributors
11.3 Glutamate Antagonist Customer
12 WORLD FORECAST REVIEW FOR GLUTAMATE ANTAGONIST BY GEOGRAPHIC REGION
12.1 Global Glutamate Antagonist Market Size Forecast by Region
12.1.1 Global Glutamate Antagonist Forecast by Region (2024-2029)
12.1.2 Global Glutamate Antagonist Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Glutamate Antagonist Forecast by Type
12.7 Global Glutamate Antagonist Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Artemis Neuroscience
13.1.1 Artemis Neuroscience Company Information
13.1.2 Artemis Neuroscience Glutamate Antagonist Product Portfolios and Specifications
13.1.3 Artemis Neuroscience Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Artemis Neuroscience Main Business Overview
13.1.5 Artemis Neuroscience Latest Developments
13.2 VistaGen Therapeutics
13.2.1 VistaGen Therapeutics Company Information
13.2.2 VistaGen Therapeutics Glutamate Antagonist Product Portfolios and Specifications
13.2.3 VistaGen Therapeutics Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 VistaGen Therapeutics Main Business Overview
13.2.5 VistaGen Therapeutics Latest Developments
13.3 Rottapharm Madaus
13.3.1 Rottapharm Madaus Company Information
13.3.2 Rottapharm Madaus Glutamate Antagonist Product Portfolios and Specifications
13.3.3 Rottapharm Madaus Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Rottapharm Madaus Main Business Overview
13.3.5 Rottapharm Madaus Latest Developments
13.4 Amorsa Therapeutics
13.4.1 Amorsa Therapeutics Company Information
13.4.2 Amorsa Therapeutics Glutamate Antagonist Product Portfolios and Specifications
13.4.3 Amorsa Therapeutics Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Amorsa Therapeutics Main Business Overview
13.4.5 Amorsa Therapeutics Latest Developments
13.5 Newron Pharmaceuticals
13.5.1 Newron Pharmaceuticals Company Information
13.5.2 Newron Pharmaceuticals Glutamate Antagonist Product Portfolios and Specifications
13.5.3 Newron Pharmaceuticals Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Newron Pharmaceuticals Main Business Overview
13.5.5 Newron Pharmaceuticals Latest Developments
13.6 Purdue Biopharma
13.6.1 Purdue Biopharma Company Information
13.6.2 Purdue Biopharma Glutamate Antagonist Product Portfolios and Specifications
13.6.3 Purdue Biopharma Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Purdue Biopharma Main Business Overview
13.6.5 Purdue Biopharma Latest Developments
13.7 Relmada Therapeutics
13.7.1 Relmada Therapeutics Company Information
13.7.2 Relmada Therapeutics Glutamate Antagonist Product Portfolios and Specifications
13.7.3 Relmada Therapeutics Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Relmada Therapeutics Main Business Overview
13.7.5 Relmada Therapeutics Latest Developments
13.8 BioCrea GmbH
13.8.1 BioCrea GmbH Company Information
13.8.2 BioCrea GmbH Glutamate Antagonist Product Portfolios and Specifications
13.8.3 BioCrea GmbH Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 BioCrea GmbH Main Business Overview
13.8.5 BioCrea GmbH Latest Developments
13.9 Cerecor Inc.
13.9.1 Cerecor Inc. Company Information
13.9.2 Cerecor Inc. Glutamate Antagonist Product Portfolios and Specifications
13.9.3 Cerecor Inc. Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Cerecor Inc. Main Business Overview
13.9.5 Cerecor Inc. Latest Developments
13.10 NeurOp Inc.
13.10.1 NeurOp Inc. Company Information
13.10.2 NeurOp Inc. Glutamate Antagonist Product Portfolios and Specifications
13.10.3 NeurOp Inc. Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 NeurOp Inc. Main Business Overview
13.10.5 NeurOp Inc. Latest Developments
13.11 UCB SA
13.11.1 UCB SA Company Information
13.11.2 UCB SA Glutamate Antagonist Product Portfolios and Specifications
13.11.3 UCB SA Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 UCB SA Main Business Overview
13.11.5 UCB SA Latest Developments
13.12 Novartis AG
13.12.1 Novartis AG Company Information
13.12.2 Novartis AG Glutamate Antagonist Product Portfolios and Specifications
13.12.3 Novartis AG Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis AG Main Business Overview
13.12.5 Novartis AG Latest Developments
13.13 Luc Therapeutics Inc.
13.13.1 Luc Therapeutics Inc. Company Information
13.13.2 Luc Therapeutics Inc. Glutamate Antagonist Product Portfolios and Specifications
13.13.3 Luc Therapeutics Inc. Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Luc Therapeutics Inc. Main Business Overview
13.13.5 Luc Therapeutics Inc. Latest Developments
13.14 Evotec AG
13.14.1 Evotec AG Company Information
13.14.2 Evotec AG Glutamate Antagonist Product Portfolios and Specifications
13.14.3 Evotec AG Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Evotec AG Main Business Overview
13.14.5 Evotec AG Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Glutamate Antagonist Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Glutamate Antagonist by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Glutamate Antagonist by Country/Region, 2018, 2022 & 2029
2.2 Glutamate Antagonist Segment by Type
2.2.1 Ionic
2.2.2 Non Ionic
2.3 Glutamate Antagonist Sales by Type
2.3.1 Global Glutamate Antagonist Sales Market Share by Type (2018-2023)
2.3.2 Global Glutamate Antagonist Revenue and Market Share by Type (2018-2023)
2.3.3 Global Glutamate Antagonist Sale Price by Type (2018-2023)
2.4 Glutamate Antagonist Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Laboratory
2.4.4 Others
2.5 Glutamate Antagonist Sales by Application
2.5.1 Global Glutamate Antagonist Sale Market Share by Application (2018-2023)
2.5.2 Global Glutamate Antagonist Revenue and Market Share by Application (2018-2023)
2.5.3 Global Glutamate Antagonist Sale Price by Application (2018-2023)
3 GLOBAL GLUTAMATE ANTAGONIST BY COMPANY
3.1 Global Glutamate Antagonist Breakdown Data by Company
3.1.1 Global Glutamate Antagonist Annual Sales by Company (2018-2023)
3.1.2 Global Glutamate Antagonist Sales Market Share by Company (2018-2023)
3.2 Global Glutamate Antagonist Annual Revenue by Company (2018-2023)
3.2.1 Global Glutamate Antagonist Revenue by Company (2018-2023)
3.2.2 Global Glutamate Antagonist Revenue Market Share by Company (2018-2023)
3.3 Global Glutamate Antagonist Sale Price by Company
3.4 Key Manufacturers Glutamate Antagonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glutamate Antagonist Product Location Distribution
3.4.2 Players Glutamate Antagonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLUTAMATE ANTAGONIST BY GEOGRAPHIC REGION
4.1 World Historic Glutamate Antagonist Market Size by Geographic Region (2018-2023)
4.1.1 Global Glutamate Antagonist Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Glutamate Antagonist Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Glutamate Antagonist Market Size by Country/Region (2018-2023)
4.2.1 Global Glutamate Antagonist Annual Sales by Country/Region (2018-2023)
4.2.2 Global Glutamate Antagonist Annual Revenue by Country/Region (2018-2023)
4.3 Americas Glutamate Antagonist Sales Growth
4.4 APAC Glutamate Antagonist Sales Growth
4.5 Europe Glutamate Antagonist Sales Growth
4.6 Middle East & Africa Glutamate Antagonist Sales Growth
5 AMERICAS
5.1 Americas Glutamate Antagonist Sales by Country
5.1.1 Americas Glutamate Antagonist Sales by Country (2018-2023)
5.1.2 Americas Glutamate Antagonist Revenue by Country (2018-2023)
5.2 Americas Glutamate Antagonist Sales by Type
5.3 Americas Glutamate Antagonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glutamate Antagonist Sales by Region
6.1.1 APAC Glutamate Antagonist Sales by Region (2018-2023)
6.1.2 APAC Glutamate Antagonist Revenue by Region (2018-2023)
6.2 APAC Glutamate Antagonist Sales by Type
6.3 APAC Glutamate Antagonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Glutamate Antagonist by Country
7.1.1 Europe Glutamate Antagonist Sales by Country (2018-2023)
7.1.2 Europe Glutamate Antagonist Revenue by Country (2018-2023)
7.2 Europe Glutamate Antagonist Sales by Type
7.3 Europe Glutamate Antagonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Glutamate Antagonist by Country
8.1.1 Middle East & Africa Glutamate Antagonist Sales by Country (2018-2023)
8.1.2 Middle East & Africa Glutamate Antagonist Revenue by Country (2018-2023)
8.2 Middle East & Africa Glutamate Antagonist Sales by Type
8.3 Middle East & Africa Glutamate Antagonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Glutamate Antagonist
10.3 Manufacturing Process Analysis of Glutamate Antagonist
10.4 Industry Chain Structure of Glutamate Antagonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Glutamate Antagonist Distributors
11.3 Glutamate Antagonist Customer
12 WORLD FORECAST REVIEW FOR GLUTAMATE ANTAGONIST BY GEOGRAPHIC REGION
12.1 Global Glutamate Antagonist Market Size Forecast by Region
12.1.1 Global Glutamate Antagonist Forecast by Region (2024-2029)
12.1.2 Global Glutamate Antagonist Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Glutamate Antagonist Forecast by Type
12.7 Global Glutamate Antagonist Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Artemis Neuroscience
13.1.1 Artemis Neuroscience Company Information
13.1.2 Artemis Neuroscience Glutamate Antagonist Product Portfolios and Specifications
13.1.3 Artemis Neuroscience Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Artemis Neuroscience Main Business Overview
13.1.5 Artemis Neuroscience Latest Developments
13.2 VistaGen Therapeutics
13.2.1 VistaGen Therapeutics Company Information
13.2.2 VistaGen Therapeutics Glutamate Antagonist Product Portfolios and Specifications
13.2.3 VistaGen Therapeutics Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 VistaGen Therapeutics Main Business Overview
13.2.5 VistaGen Therapeutics Latest Developments
13.3 Rottapharm Madaus
13.3.1 Rottapharm Madaus Company Information
13.3.2 Rottapharm Madaus Glutamate Antagonist Product Portfolios and Specifications
13.3.3 Rottapharm Madaus Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Rottapharm Madaus Main Business Overview
13.3.5 Rottapharm Madaus Latest Developments
13.4 Amorsa Therapeutics
13.4.1 Amorsa Therapeutics Company Information
13.4.2 Amorsa Therapeutics Glutamate Antagonist Product Portfolios and Specifications
13.4.3 Amorsa Therapeutics Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Amorsa Therapeutics Main Business Overview
13.4.5 Amorsa Therapeutics Latest Developments
13.5 Newron Pharmaceuticals
13.5.1 Newron Pharmaceuticals Company Information
13.5.2 Newron Pharmaceuticals Glutamate Antagonist Product Portfolios and Specifications
13.5.3 Newron Pharmaceuticals Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Newron Pharmaceuticals Main Business Overview
13.5.5 Newron Pharmaceuticals Latest Developments
13.6 Purdue Biopharma
13.6.1 Purdue Biopharma Company Information
13.6.2 Purdue Biopharma Glutamate Antagonist Product Portfolios and Specifications
13.6.3 Purdue Biopharma Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Purdue Biopharma Main Business Overview
13.6.5 Purdue Biopharma Latest Developments
13.7 Relmada Therapeutics
13.7.1 Relmada Therapeutics Company Information
13.7.2 Relmada Therapeutics Glutamate Antagonist Product Portfolios and Specifications
13.7.3 Relmada Therapeutics Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Relmada Therapeutics Main Business Overview
13.7.5 Relmada Therapeutics Latest Developments
13.8 BioCrea GmbH
13.8.1 BioCrea GmbH Company Information
13.8.2 BioCrea GmbH Glutamate Antagonist Product Portfolios and Specifications
13.8.3 BioCrea GmbH Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 BioCrea GmbH Main Business Overview
13.8.5 BioCrea GmbH Latest Developments
13.9 Cerecor Inc.
13.9.1 Cerecor Inc. Company Information
13.9.2 Cerecor Inc. Glutamate Antagonist Product Portfolios and Specifications
13.9.3 Cerecor Inc. Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Cerecor Inc. Main Business Overview
13.9.5 Cerecor Inc. Latest Developments
13.10 NeurOp Inc.
13.10.1 NeurOp Inc. Company Information
13.10.2 NeurOp Inc. Glutamate Antagonist Product Portfolios and Specifications
13.10.3 NeurOp Inc. Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 NeurOp Inc. Main Business Overview
13.10.5 NeurOp Inc. Latest Developments
13.11 UCB SA
13.11.1 UCB SA Company Information
13.11.2 UCB SA Glutamate Antagonist Product Portfolios and Specifications
13.11.3 UCB SA Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 UCB SA Main Business Overview
13.11.5 UCB SA Latest Developments
13.12 Novartis AG
13.12.1 Novartis AG Company Information
13.12.2 Novartis AG Glutamate Antagonist Product Portfolios and Specifications
13.12.3 Novartis AG Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Novartis AG Main Business Overview
13.12.5 Novartis AG Latest Developments
13.13 Luc Therapeutics Inc.
13.13.1 Luc Therapeutics Inc. Company Information
13.13.2 Luc Therapeutics Inc. Glutamate Antagonist Product Portfolios and Specifications
13.13.3 Luc Therapeutics Inc. Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Luc Therapeutics Inc. Main Business Overview
13.13.5 Luc Therapeutics Inc. Latest Developments
13.14 Evotec AG
13.14.1 Evotec AG Company Information
13.14.2 Evotec AG Glutamate Antagonist Product Portfolios and Specifications
13.14.3 Evotec AG Glutamate Antagonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Evotec AG Main Business Overview
13.14.5 Evotec AG Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Glutamate Antagonist Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Glutamate Antagonist Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Ionic
Table 4. Major Players of Non Ionic
Table 5. Global Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 6. Global Glutamate Antagonist Sales Market Share by Type (2018-2023)
Table 7. Global Glutamate Antagonist Revenue by Type (2018-2023) & ($ million)
Table 8. Global Glutamate Antagonist Revenue Market Share by Type (2018-2023)
Table 9. Global Glutamate Antagonist Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 11. Global Glutamate Antagonist Sales Market Share by Application (2018-2023)
Table 12. Global Glutamate Antagonist Revenue by Application (2018-2023)
Table 13. Global Glutamate Antagonist Revenue Market Share by Application (2018-2023)
Table 14. Global Glutamate Antagonist Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Glutamate Antagonist Sales by Company (2018-2023) & (Units)
Table 16. Global Glutamate Antagonist Sales Market Share by Company (2018-2023)
Table 17. Global Glutamate Antagonist Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Glutamate Antagonist Revenue Market Share by Company (2018-2023)
Table 19. Global Glutamate Antagonist Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Glutamate Antagonist Producing Area Distribution and Sales Area
Table 21. Players Glutamate Antagonist Products Offered
Table 22. Glutamate Antagonist Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Glutamate Antagonist Sales by Geographic Region (2018-2023) & (Units)
Table 26. Global Glutamate Antagonist Sales Market Share Geographic Region (2018-2023)
Table 27. Global Glutamate Antagonist Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Glutamate Antagonist Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Glutamate Antagonist Sales by Country/Region (2018-2023) & (Units)
Table 30. Global Glutamate Antagonist Sales Market Share by Country/Region (2018-2023)
Table 31. Global Glutamate Antagonist Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Glutamate Antagonist Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Glutamate Antagonist Sales by Country (2018-2023) & (Units)
Table 34. Americas Glutamate Antagonist Sales Market Share by Country (2018-2023)
Table 35. Americas Glutamate Antagonist Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Glutamate Antagonist Revenue Market Share by Country (2018-2023)
Table 37. Americas Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 38. Americas Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 39. APAC Glutamate Antagonist Sales by Region (2018-2023) & (Units)
Table 40. APAC Glutamate Antagonist Sales Market Share by Region (2018-2023)
Table 41. APAC Glutamate Antagonist Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Glutamate Antagonist Revenue Market Share by Region (2018-2023)
Table 43. APAC Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 44. APAC Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 45. Europe Glutamate Antagonist Sales by Country (2018-2023) & (Units)
Table 46. Europe Glutamate Antagonist Sales Market Share by Country (2018-2023)
Table 47. Europe Glutamate Antagonist Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Glutamate Antagonist Revenue Market Share by Country (2018-2023)
Table 49. Europe Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 50. Europe Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 51. Middle East & Africa Glutamate Antagonist Sales by Country (2018-2023) & (Units)
Table 52. Middle East & Africa Glutamate Antagonist Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Glutamate Antagonist Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Glutamate Antagonist Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 56. Middle East & Africa Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of Glutamate Antagonist
Table 58. Key Market Challenges & Risks of Glutamate Antagonist
Table 59. Key Industry Trends of Glutamate Antagonist
Table 60. Glutamate Antagonist Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Glutamate Antagonist Distributors List
Table 63. Glutamate Antagonist Customer List
Table 64. Global Glutamate Antagonist Sales Forecast by Region (2024-2029) & (Units)
Table 65. Global Glutamate Antagonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Glutamate Antagonist Sales Forecast by Country (2024-2029) & (Units)
Table 67. Americas Glutamate Antagonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Glutamate Antagonist Sales Forecast by Region (2024-2029) & (Units)
Table 69. APAC Glutamate Antagonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Glutamate Antagonist Sales Forecast by Country (2024-2029) & (Units)
Table 71. Europe Glutamate Antagonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Glutamate Antagonist Sales Forecast by Country (2024-2029) & (Units)
Table 73. Middle East & Africa Glutamate Antagonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Glutamate Antagonist Sales Forecast by Type (2024-2029) & (Units)
Table 75. Global Glutamate Antagonist Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Glutamate Antagonist Sales Forecast by Application (2024-2029) & (Units)
Table 77. Global Glutamate Antagonist Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Artemis Neuroscience Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 79. Artemis Neuroscience Glutamate Antagonist Product Portfolios and Specifications
Table 80. Artemis Neuroscience Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Artemis Neuroscience Main Business
Table 82. Artemis Neuroscience Latest Developments
Table 83. VistaGen Therapeutics Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 84. VistaGen Therapeutics Glutamate Antagonist Product Portfolios and Specifications
Table 85. VistaGen Therapeutics Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. VistaGen Therapeutics Main Business
Table 87. VistaGen Therapeutics Latest Developments
Table 88. Rottapharm Madaus Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 89. Rottapharm Madaus Glutamate Antagonist Product Portfolios and Specifications
Table 90. Rottapharm Madaus Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Rottapharm Madaus Main Business
Table 92. Rottapharm Madaus Latest Developments
Table 93. Amorsa Therapeutics Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 94. Amorsa Therapeutics Glutamate Antagonist Product Portfolios and Specifications
Table 95. Amorsa Therapeutics Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Amorsa Therapeutics Main Business
Table 97. Amorsa Therapeutics Latest Developments
Table 98. Newron Pharmaceuticals Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 99. Newron Pharmaceuticals Glutamate Antagonist Product Portfolios and Specifications
Table 100. Newron Pharmaceuticals Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Newron Pharmaceuticals Main Business
Table 102. Newron Pharmaceuticals Latest Developments
Table 103. Purdue Biopharma Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 104. Purdue Biopharma Glutamate Antagonist Product Portfolios and Specifications
Table 105. Purdue Biopharma Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Purdue Biopharma Main Business
Table 107. Purdue Biopharma Latest Developments
Table 108. Relmada Therapeutics Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 109. Relmada Therapeutics Glutamate Antagonist Product Portfolios and Specifications
Table 110. Relmada Therapeutics Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Relmada Therapeutics Main Business
Table 112. Relmada Therapeutics Latest Developments
Table 113. BioCrea GmbH Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 114. BioCrea GmbH Glutamate Antagonist Product Portfolios and Specifications
Table 115. BioCrea GmbH Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. BioCrea GmbH Main Business
Table 117. BioCrea GmbH Latest Developments
Table 118. Cerecor Inc. Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 119. Cerecor Inc. Glutamate Antagonist Product Portfolios and Specifications
Table 120. Cerecor Inc. Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Cerecor Inc. Main Business
Table 122. Cerecor Inc. Latest Developments
Table 123. NeurOp Inc. Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 124. NeurOp Inc. Glutamate Antagonist Product Portfolios and Specifications
Table 125. NeurOp Inc. Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. NeurOp Inc. Main Business
Table 127. NeurOp Inc. Latest Developments
Table 128. UCB SA Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 129. UCB SA Glutamate Antagonist Product Portfolios and Specifications
Table 130. UCB SA Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. UCB SA Main Business
Table 132. UCB SA Latest Developments
Table 133. Novartis AG Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 134. Novartis AG Glutamate Antagonist Product Portfolios and Specifications
Table 135. Novartis AG Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Novartis AG Main Business
Table 137. Novartis AG Latest Developments
Table 138. Luc Therapeutics Inc. Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 139. Luc Therapeutics Inc. Glutamate Antagonist Product Portfolios and Specifications
Table 140. Luc Therapeutics Inc. Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 141. Luc Therapeutics Inc. Main Business
Table 142. Luc Therapeutics Inc. Latest Developments
Table 143. Evotec AG Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 144. Evotec AG Glutamate Antagonist Product Portfolios and Specifications
Table 145. Evotec AG Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 146. Evotec AG Main Business
Table 147. Evotec AG Latest Developments
Table 1. Glutamate Antagonist Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Glutamate Antagonist Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Ionic
Table 4. Major Players of Non Ionic
Table 5. Global Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 6. Global Glutamate Antagonist Sales Market Share by Type (2018-2023)
Table 7. Global Glutamate Antagonist Revenue by Type (2018-2023) & ($ million)
Table 8. Global Glutamate Antagonist Revenue Market Share by Type (2018-2023)
Table 9. Global Glutamate Antagonist Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 11. Global Glutamate Antagonist Sales Market Share by Application (2018-2023)
Table 12. Global Glutamate Antagonist Revenue by Application (2018-2023)
Table 13. Global Glutamate Antagonist Revenue Market Share by Application (2018-2023)
Table 14. Global Glutamate Antagonist Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Glutamate Antagonist Sales by Company (2018-2023) & (Units)
Table 16. Global Glutamate Antagonist Sales Market Share by Company (2018-2023)
Table 17. Global Glutamate Antagonist Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Glutamate Antagonist Revenue Market Share by Company (2018-2023)
Table 19. Global Glutamate Antagonist Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Glutamate Antagonist Producing Area Distribution and Sales Area
Table 21. Players Glutamate Antagonist Products Offered
Table 22. Glutamate Antagonist Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Glutamate Antagonist Sales by Geographic Region (2018-2023) & (Units)
Table 26. Global Glutamate Antagonist Sales Market Share Geographic Region (2018-2023)
Table 27. Global Glutamate Antagonist Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Glutamate Antagonist Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Glutamate Antagonist Sales by Country/Region (2018-2023) & (Units)
Table 30. Global Glutamate Antagonist Sales Market Share by Country/Region (2018-2023)
Table 31. Global Glutamate Antagonist Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Glutamate Antagonist Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Glutamate Antagonist Sales by Country (2018-2023) & (Units)
Table 34. Americas Glutamate Antagonist Sales Market Share by Country (2018-2023)
Table 35. Americas Glutamate Antagonist Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Glutamate Antagonist Revenue Market Share by Country (2018-2023)
Table 37. Americas Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 38. Americas Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 39. APAC Glutamate Antagonist Sales by Region (2018-2023) & (Units)
Table 40. APAC Glutamate Antagonist Sales Market Share by Region (2018-2023)
Table 41. APAC Glutamate Antagonist Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Glutamate Antagonist Revenue Market Share by Region (2018-2023)
Table 43. APAC Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 44. APAC Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 45. Europe Glutamate Antagonist Sales by Country (2018-2023) & (Units)
Table 46. Europe Glutamate Antagonist Sales Market Share by Country (2018-2023)
Table 47. Europe Glutamate Antagonist Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Glutamate Antagonist Revenue Market Share by Country (2018-2023)
Table 49. Europe Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 50. Europe Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 51. Middle East & Africa Glutamate Antagonist Sales by Country (2018-2023) & (Units)
Table 52. Middle East & Africa Glutamate Antagonist Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Glutamate Antagonist Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Glutamate Antagonist Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Glutamate Antagonist Sales by Type (2018-2023) & (Units)
Table 56. Middle East & Africa Glutamate Antagonist Sales by Application (2018-2023) & (Units)
Table 57. Key Market Drivers & Growth Opportunities of Glutamate Antagonist
Table 58. Key Market Challenges & Risks of Glutamate Antagonist
Table 59. Key Industry Trends of Glutamate Antagonist
Table 60. Glutamate Antagonist Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Glutamate Antagonist Distributors List
Table 63. Glutamate Antagonist Customer List
Table 64. Global Glutamate Antagonist Sales Forecast by Region (2024-2029) & (Units)
Table 65. Global Glutamate Antagonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Glutamate Antagonist Sales Forecast by Country (2024-2029) & (Units)
Table 67. Americas Glutamate Antagonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Glutamate Antagonist Sales Forecast by Region (2024-2029) & (Units)
Table 69. APAC Glutamate Antagonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Glutamate Antagonist Sales Forecast by Country (2024-2029) & (Units)
Table 71. Europe Glutamate Antagonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Glutamate Antagonist Sales Forecast by Country (2024-2029) & (Units)
Table 73. Middle East & Africa Glutamate Antagonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Glutamate Antagonist Sales Forecast by Type (2024-2029) & (Units)
Table 75. Global Glutamate Antagonist Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Glutamate Antagonist Sales Forecast by Application (2024-2029) & (Units)
Table 77. Global Glutamate Antagonist Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Artemis Neuroscience Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 79. Artemis Neuroscience Glutamate Antagonist Product Portfolios and Specifications
Table 80. Artemis Neuroscience Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Artemis Neuroscience Main Business
Table 82. Artemis Neuroscience Latest Developments
Table 83. VistaGen Therapeutics Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 84. VistaGen Therapeutics Glutamate Antagonist Product Portfolios and Specifications
Table 85. VistaGen Therapeutics Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. VistaGen Therapeutics Main Business
Table 87. VistaGen Therapeutics Latest Developments
Table 88. Rottapharm Madaus Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 89. Rottapharm Madaus Glutamate Antagonist Product Portfolios and Specifications
Table 90. Rottapharm Madaus Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Rottapharm Madaus Main Business
Table 92. Rottapharm Madaus Latest Developments
Table 93. Amorsa Therapeutics Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 94. Amorsa Therapeutics Glutamate Antagonist Product Portfolios and Specifications
Table 95. Amorsa Therapeutics Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Amorsa Therapeutics Main Business
Table 97. Amorsa Therapeutics Latest Developments
Table 98. Newron Pharmaceuticals Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 99. Newron Pharmaceuticals Glutamate Antagonist Product Portfolios and Specifications
Table 100. Newron Pharmaceuticals Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Newron Pharmaceuticals Main Business
Table 102. Newron Pharmaceuticals Latest Developments
Table 103. Purdue Biopharma Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 104. Purdue Biopharma Glutamate Antagonist Product Portfolios and Specifications
Table 105. Purdue Biopharma Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Purdue Biopharma Main Business
Table 107. Purdue Biopharma Latest Developments
Table 108. Relmada Therapeutics Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 109. Relmada Therapeutics Glutamate Antagonist Product Portfolios and Specifications
Table 110. Relmada Therapeutics Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Relmada Therapeutics Main Business
Table 112. Relmada Therapeutics Latest Developments
Table 113. BioCrea GmbH Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 114. BioCrea GmbH Glutamate Antagonist Product Portfolios and Specifications
Table 115. BioCrea GmbH Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. BioCrea GmbH Main Business
Table 117. BioCrea GmbH Latest Developments
Table 118. Cerecor Inc. Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 119. Cerecor Inc. Glutamate Antagonist Product Portfolios and Specifications
Table 120. Cerecor Inc. Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Cerecor Inc. Main Business
Table 122. Cerecor Inc. Latest Developments
Table 123. NeurOp Inc. Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 124. NeurOp Inc. Glutamate Antagonist Product Portfolios and Specifications
Table 125. NeurOp Inc. Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. NeurOp Inc. Main Business
Table 127. NeurOp Inc. Latest Developments
Table 128. UCB SA Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 129. UCB SA Glutamate Antagonist Product Portfolios and Specifications
Table 130. UCB SA Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. UCB SA Main Business
Table 132. UCB SA Latest Developments
Table 133. Novartis AG Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 134. Novartis AG Glutamate Antagonist Product Portfolios and Specifications
Table 135. Novartis AG Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Novartis AG Main Business
Table 137. Novartis AG Latest Developments
Table 138. Luc Therapeutics Inc. Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 139. Luc Therapeutics Inc. Glutamate Antagonist Product Portfolios and Specifications
Table 140. Luc Therapeutics Inc. Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 141. Luc Therapeutics Inc. Main Business
Table 142. Luc Therapeutics Inc. Latest Developments
Table 143. Evotec AG Basic Information, Glutamate Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 144. Evotec AG Glutamate Antagonist Product Portfolios and Specifications
Table 145. Evotec AG Glutamate Antagonist Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 146. Evotec AG Main Business
Table 147. Evotec AG Latest Developments
LIST OF FIGURES
Figure 1. Picture of Glutamate Antagonist
Figure 2. Glutamate Antagonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glutamate Antagonist Sales Growth Rate 2018-2029 (Units)
Figure 7. Global Glutamate Antagonist Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Glutamate Antagonist Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Ionic
Figure 10. Product Picture of Non Ionic
Figure 11. Global Glutamate Antagonist Sales Market Share by Type in 2022
Figure 12. Global Glutamate Antagonist Revenue Market Share by Type (2018-2023)
Figure 13. Glutamate Antagonist Consumed in Hospitals
Figure 14. Global Glutamate Antagonist Market: Hospitals (2018-2023) & (Units)
Figure 15. Glutamate Antagonist Consumed in Clinics
Figure 16. Global Glutamate Antagonist Market: Clinics (2018-2023) & (Units)
Figure 17. Glutamate Antagonist Consumed in Laboratory
Figure 18. Global Glutamate Antagonist Market: Laboratory (2018-2023) & (Units)
Figure 19. Glutamate Antagonist Consumed in Others
Figure 20. Global Glutamate Antagonist Market: Others (2018-2023) & (Units)
Figure 21. Global Glutamate Antagonist Sales Market Share by Application (2022)
Figure 22. Global Glutamate Antagonist Revenue Market Share by Application in 2022
Figure 23. Glutamate Antagonist Sales Market by Company in 2022 (Units)
Figure 24. Global Glutamate Antagonist Sales Market Share by Company in 2022
Figure 25. Glutamate Antagonist Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Glutamate Antagonist Revenue Market Share by Company in 2022
Figure 27. Global Glutamate Antagonist Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Glutamate Antagonist Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Glutamate Antagonist Sales 2018-2023 (Units)
Figure 30. Americas Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 31. APAC Glutamate Antagonist Sales 2018-2023 (Units)
Figure 32. APAC Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 33. Europe Glutamate Antagonist Sales 2018-2023 (Units)
Figure 34. Europe Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Glutamate Antagonist Sales 2018-2023 (Units)
Figure 36. Middle East & Africa Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 37. Americas Glutamate Antagonist Sales Market Share by Country in 2022
Figure 38. Americas Glutamate Antagonist Revenue Market Share by Country in 2022
Figure 39. Americas Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 40. Americas Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 41. United States Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Glutamate Antagonist Sales Market Share by Region in 2022
Figure 46. APAC Glutamate Antagonist Revenue Market Share by Regions in 2022
Figure 47. APAC Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 48. APAC Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 49. China Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Glutamate Antagonist Sales Market Share by Country in 2022
Figure 57. Europe Glutamate Antagonist Revenue Market Share by Country in 2022
Figure 58. Europe Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 59. Europe Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 60. Germany Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Glutamate Antagonist Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Glutamate Antagonist Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 69. Egypt Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Glutamate Antagonist in 2022
Figure 75. Manufacturing Process Analysis of Glutamate Antagonist
Figure 76. Industry Chain Structure of Glutamate Antagonist
Figure 77. Channels of Distribution
Figure 78. Global Glutamate Antagonist Sales Market Forecast by Region (2024-2029)
Figure 79. Global Glutamate Antagonist Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Glutamate Antagonist Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Glutamate Antagonist Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Glutamate Antagonist Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Glutamate Antagonist Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Glutamate Antagonist
Figure 2. Glutamate Antagonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glutamate Antagonist Sales Growth Rate 2018-2029 (Units)
Figure 7. Global Glutamate Antagonist Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Glutamate Antagonist Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Ionic
Figure 10. Product Picture of Non Ionic
Figure 11. Global Glutamate Antagonist Sales Market Share by Type in 2022
Figure 12. Global Glutamate Antagonist Revenue Market Share by Type (2018-2023)
Figure 13. Glutamate Antagonist Consumed in Hospitals
Figure 14. Global Glutamate Antagonist Market: Hospitals (2018-2023) & (Units)
Figure 15. Glutamate Antagonist Consumed in Clinics
Figure 16. Global Glutamate Antagonist Market: Clinics (2018-2023) & (Units)
Figure 17. Glutamate Antagonist Consumed in Laboratory
Figure 18. Global Glutamate Antagonist Market: Laboratory (2018-2023) & (Units)
Figure 19. Glutamate Antagonist Consumed in Others
Figure 20. Global Glutamate Antagonist Market: Others (2018-2023) & (Units)
Figure 21. Global Glutamate Antagonist Sales Market Share by Application (2022)
Figure 22. Global Glutamate Antagonist Revenue Market Share by Application in 2022
Figure 23. Glutamate Antagonist Sales Market by Company in 2022 (Units)
Figure 24. Global Glutamate Antagonist Sales Market Share by Company in 2022
Figure 25. Glutamate Antagonist Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Glutamate Antagonist Revenue Market Share by Company in 2022
Figure 27. Global Glutamate Antagonist Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Glutamate Antagonist Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Glutamate Antagonist Sales 2018-2023 (Units)
Figure 30. Americas Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 31. APAC Glutamate Antagonist Sales 2018-2023 (Units)
Figure 32. APAC Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 33. Europe Glutamate Antagonist Sales 2018-2023 (Units)
Figure 34. Europe Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Glutamate Antagonist Sales 2018-2023 (Units)
Figure 36. Middle East & Africa Glutamate Antagonist Revenue 2018-2023 ($ Millions)
Figure 37. Americas Glutamate Antagonist Sales Market Share by Country in 2022
Figure 38. Americas Glutamate Antagonist Revenue Market Share by Country in 2022
Figure 39. Americas Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 40. Americas Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 41. United States Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Glutamate Antagonist Sales Market Share by Region in 2022
Figure 46. APAC Glutamate Antagonist Revenue Market Share by Regions in 2022
Figure 47. APAC Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 48. APAC Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 49. China Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Glutamate Antagonist Sales Market Share by Country in 2022
Figure 57. Europe Glutamate Antagonist Revenue Market Share by Country in 2022
Figure 58. Europe Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 59. Europe Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 60. Germany Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Glutamate Antagonist Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Glutamate Antagonist Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Glutamate Antagonist Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Glutamate Antagonist Sales Market Share by Application (2018-2023)
Figure 69. Egypt Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Glutamate Antagonist Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Glutamate Antagonist in 2022
Figure 75. Manufacturing Process Analysis of Glutamate Antagonist
Figure 76. Industry Chain Structure of Glutamate Antagonist
Figure 77. Channels of Distribution
Figure 78. Global Glutamate Antagonist Sales Market Forecast by Region (2024-2029)
Figure 79. Global Glutamate Antagonist Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Glutamate Antagonist Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Glutamate Antagonist Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Glutamate Antagonist Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Glutamate Antagonist Revenue Market Share Forecast by Application (2024-2029)
